What targets does Erlotinib target?

Erlotinib (Erlotinib) is an oral small molecule tyrosine kinase inhibitor that mainly targets epidermal growth factor receptor (EGFR). EGFR is a receptor protein located on the cell membrane, involved in regulating cell proliferation, differentiation and survival. Erlotinib inhibits the growth and spread of tumor cells by competitively inhibiting the tyrosine kinase activity of EGFR and blocking its downstream signaling pathways.

The EGFR gene is often mutated or overexpressed in a variety of tumors, especially in patients with non-small cell lung cancer (NSCLC). Erlotinib targets mutations of EGFR, especially exon 19 deletion and 21 point mutation (L858R) has a high inhibitory effect, can significantly delay the progression of tumors, and improve the survival rate and quality of life of patients.

In addition to non-small cell lung cancer, erlotinib is also approved for the treatment of other EGFR related tumors such as pancreatic cancer. Its mechanism of action relies on targeting EGFR tyrosine kinase, inhibiting intracellular signaling pathways, such as RAS-RAF-MEK-ERK and PI3K-AKT, etc., blocking the proliferation of tumor cells and inducing apoptosis.

In general, erlotinib is a targeted anti-cancer drug that focuses on the EGFR target. It effectively interferes with tumor growth signals by inhibiting the tyrosine kinase activity of EGFR. It is especially suitable for patients with non-small cell lung cancer who carry EGFR sensitive mutations. When using this drug, patients should undergo genetic testing and efficacy evaluation under the guidance of a doctor to obtain the best therapeutic effect.

Reference:https://en.wikipedia.org/wiki/Erlotinib